A citation-based method for searching scientific literature

Bruce Neal, Vlado Perkovic, Dick de Zeeuw, Kenneth W Mahaffey, Greg Fulcher, Kirk Ways, Mehul Desai, Wayne Shaw, George Capuano, Maria Alba, Joel Jiang, Frank Vercruysse, Gary Meininger, David Matthews. Diabetes Care 2015
Times Cited: 156



J-F Yale, G Bakris, B Cariou, J Nieto, E David-Neto, D Yue, E Wajs, K Figueroa, J Jiang, G Law, K Usiskin, G Meininger. Diabetes Obes Metab 2014
Times Cited: 158




List of shared articles



Times cited

The Beneficial Hemodynamic Actions of SGLT-2 Inhibitors beyond the Management of Hyperglycemia.
Charalampos Loutradis, Eirini Papadopoulou, Elena Angeloudi, Asterios Karagiannis, Pantelis Sarafidis. Curr Med Chem 2020
11

Control of 24-hour blood pressure with SGLT2 inhibitors to prevent cardiovascular disease.
Kazuomi Kario, Keith C Ferdinand, James H O'Keefe. Prog Cardiovasc Dis 2020
12

Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: A randomized clinical trial.
Hideka Inoue, Katsutaro Morino, Satoshi Ugi, Sachiko Tanaka-Mizuno, Keiko Fuse, Itsuko Miyazawa, Keiko Kondo, Daisuke Sato, Natsuko Ohashi, Shogo Ida,[...]. J Diabetes Investig 2019
17

Inhibition of the sodium-glucose co-transporter 2 in the elderly: clinical and mechanistic insights into safety and efficacy.
Riobaldo Cintra, Filipe A Moura, Luis Sergio F de Carvalho, Joaquim Barreto, Marcos Tambascia, Roberto Pecoits-Filho, Andrei C Sposito. Rev Assoc Med Bras (1992) 2019
9

Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis.
Jennifer R Donnan, Catherine A Grandy, Eugene Chibrikov, Carlo A Marra, Kris Aubrey-Bassler, Karissa Johnston, Michelle Swab, Jenna Hache, Daniel Curnew, Hai Nguyen,[...]. BMJ Open 2019
60

Effects of SGLT2 inhibitors on fractures and bone mineral density in type 2 diabetes: An updated meta-analysis.
Xiaoyu Li, Ting Li, Ying Cheng, Yunhong Lu, Mei Xue, Linxin Xu, Xiangyang Liu, Xiaochen Yu, Bei Sun, Liming Chen. Diabetes Metab Res Rev 2019
14


The effect of SGLT-2 inhibitors on blood pressure: a pleiotropic action favoring cardio- and nephroprotection.
Charalampos Loutradis, Eirini Papadopoulou, Marietta Theodorakopoulou, Asterios Karagiannis, Pantelis Sarafidis. Future Med Chem 2019
13

Sodium-Glucose Cotransporter-2 Inhibitors, Reverse J-Curve Pattern, and Mortality in Heart Failure.
Konstantinos Imprialos, Konstantinos Stavropoulos, Vasilios Papademetriou. Heart Fail Clin 2019
0

Pharmacokinetics and pharmacodynamics of canagliflozin in pediatric patients with type 2 diabetes.
William V Tamborlane, David Polidori, Domenick Argenti, Nicholas A Di Prospero. Pediatr Diabetes 2018
1

SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: A systematic review and meta-analysis.
Samuel Seidu, Setor K Kunutsor, Xavier Cos, Syed Gillani, Kamlesh Khunti. Prim Care Diabetes 2018
36


Longer-term safety and tolerability of canagliflozin in patients with type 2 diabetes: a pooled analysis.
Rong Qiu, Dainius Balis, John Xie, Michael J Davies, Mehul Desai, Gary Meininger. Curr Med Res Opin 2017
20

Canagliflozin improves risk factors of metabolic syndrome in patients with type 2 diabetes mellitus and metabolic syndrome.
Michael J Davies, Katherine W Merton, Ujjwala Vijapurkar, Dainius A Balis, Mehul Desai. Diabetes Metab Syndr Obes 2017
8

Therapeutic Considerations for Antihyperglycemic Agents in Diabetic Kidney Disease.
Joshua J Neumiller, Radica Z Alicic, Katherine R Tuttle. J Am Soc Nephrol 2017
35


The effect of SGLT2 inhibitors on cardiovascular events and renal function.
Konstantinos P Imprialos, Konstantinos Stavropoulos, Michael Doumas, Asterios Karagiannis, Vasilios G Athyros. Expert Rev Clin Pharmacol 2017
7

Tolerability of canagliflozin in patients with type 2 diabetes mellitus fasting during Ramadan: Results of the Canagliflozin in Ramadan Tolerance Observational Study (CRATOS).
Mohamed Hassanein, Akram Echtay, Ahmed Hassoun, Monira Alarouj, Bachar Afandi, Raffi Poladian, Abdullah Bennakhi, Maciej Nazar, Paul Bergmans, Sofia Keim,[...]. Int J Clin Pract 2017
22

Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes.
G Fulcher, D R Matthews, V Perkovic, D de Zeeuw, K W Mahaffey, C Mathieu, V Woo, C Wysham, G Capuano, M Desai,[...]. Diabetes Obes Metab 2016
52